Kos Pharmaceuticals, Inc.
Records under this name other than patents Kos Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Kos Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,155,251 | Breath coordinated inhaler Formerly held Term ended Term ended Mar 4, 2019 · From the USPTO record | Term ended | Term ended Mar 4, 2019 | From the USPTO record |
| US 6,090,830 | Controlled release compositions and methods for the treatment of hyperlipidemia Formerly held Term ended Term ended Jul 20, 2018 · From the USPTO record | Term ended | Term ended Jul 20, 2018 | From the USPTO record |
| US 7,074,388 | Water Stabilized Medicinal Aerosol Formulation Formerly held Lapsed on the fee record Ended Jul 11, 2018 · Low confidence | Lapsed on the fee record | Ended Jul 11, 2018 | Low confidence |
| US 6,469,035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid Formerly held Term ended Term ended Mar 15, 2018 · From the USPTO record | Term ended | Term ended Mar 15, 2018 | From the USPTO record |
| US 6,106,606 | Spherical particles on the basis of metal oxides, method for its manufacture and its utilization Formerly held Term ended Term ended Oct 29, 2017 · From the USPTO record | Term ended | Term ended Oct 29, 2017 | From the USPTO record |
| US 6,080,428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor Formerly held Term ended Term ended Jun 27, 2017 · From the USPTO record | Term ended | Term ended Jun 27, 2017 | From the USPTO record |
| US 6,129,930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night Formerly held Term ended Term ended Mar 6, 2017 · From the USPTO record | Term ended | Term ended Mar 6, 2017 | From the USPTO record |
| US 6,020,305 | Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors Formerly held Term ended Term ended Aug 6, 2016 · From the USPTO record | Term ended | Term ended Aug 6, 2016 | From the USPTO record |
| US 6,596,308 | Controlled release pharmaceutical composition Formerly held Lapsed on the fee record Ended Jul 22, 2015 · From the USPTO record | Lapsed on the fee record | Ended Jul 22, 2015 | From the USPTO record |
| US 6,524,615 | Controlled release pharmaceutical composition Formerly held Lapsed on the fee record Ended Feb 25, 2015 · From the USPTO record | Lapsed on the fee record | Ended Feb 25, 2015 | From the USPTO record |